Literature DB >> 11354594

Work rehabilitation in schizophrenia: does cognitive impairment limit improvement?

M D Bell1, G Bryson.   

Abstract

Cognitive impairments may be an important contributor to disability in schizophrenia and may limit the rate of improvement in work rehabilitation. Thirty-three outpatients with schizophrenia or schizoaffective disorder who participated in a 6-month work rehabilitation program were assessed for symptom severity and administered neuropsychological testing at intake. Their work performance was evaluated biweekly using the Work Behavior Inventory. On each of five domains of work performance, 76 to 91 percent of subjects reached proficiency or improved significantly over 26 weeks. Individual differences in rate of improvement were robustly predicted by neuropsychological variables: Work Habits, r2 = 0.79; Personal Presentation, r2 = 0.73; Cooperativeness, r2 = 0.67; Work Quality, r2 = 0.56; Social Skills, r2 = 0.27; Total, r2 = 0.44. Neuropsychological measures had differential relationships to work domains. Individual differences in improvement were not predicted by symptom measures. These findings link cognitive impairment to disability and suggest that remediating or accommodating such deficits may be necessary for successful rehabilitation.

Entities:  

Mesh:

Year:  2001        PMID: 11354594     DOI: 10.1093/oxfordjournals.schbul.a006873

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  34 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 2.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

3.  Ecological assessment of executive dysfunction in the psychosis prodrome: a pilot study.

Authors:  Tara A Niendam; Jacqueline Horwitz; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2007-04-30       Impact factor: 4.939

Review 4.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

5.  Social skills training and computer-assisted cognitive remediation in schizophrenia.

Authors:  Matthew M Kurtz; Kim T Mueser; Warren R Thime; Silvia Corbera; Bruce E Wexler
Journal:  Schizophr Res       Date:  2015-01-29       Impact factor: 4.939

Review 6.  Neurocognition as a predictor of response to evidence-based psychosocial interventions in schizophrenia: what is the state of the evidence?

Authors:  Matthew M Kurtz
Journal:  Clin Psychol Rev       Date:  2011-02-26

Review 7.  Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies.

Authors:  Tarek K Rajji; Dielle Miranda; Benoit H Mulsant
Journal:  Can J Psychiatry       Date:  2014-01       Impact factor: 4.356

8.  Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches.

Authors:  Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell
Journal:  Am J Psychiatr Rehabil       Date:  2014-07

9.  Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.

Authors:  Melissa Fisher; Christine Holland; Michael M Merzenich; Sophia Vinogradov
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

10.  Occupational functioning, symptoms and neurocognition in patients with psychotic disorders: investigating subgroups based on social security status.

Authors:  Marte Tandberg; Kjetil Sundet; Ole A Andreassen; Ingrid Melle; Torill Ueland
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-13       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.